| Literature DB >> 35378954 |
Mateusz Maciejczyk1, Miłosz Nesterowicz2, Julita Szulimowska3, Anna Zalewska3.
Abstract
Background: Aging is inextricably linked to oxidative stress, inflammation, and posttranslational protein modifications. However, no studies evaluate oxidation, glycation, and carbamylation of salivary biomolecules as biomarkers of aging. Saliva collection is non-invasive, painless, and inexpensive, which are advantages over other biofluids.Entities:
Keywords: DNA oxidation; aging; protein carbamylation; protein glycation; protein oxidation; saliva
Year: 2022 PMID: 35378954 PMCID: PMC8976116 DOI: 10.2147/JIR.S356029
Source DB: PubMed Journal: J Inflamm Res ISSN: 1178-7031
Clinical Characteristics of Healthy Subjects Aged 6–13, 14–19, 20–39, 40–59, 60–79, and 80–100
| 6–13 | 14–19 | 20–39 | 40–59 | 60–79 | 80–100 | ANOVA p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | ||
| (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | ||
| Age | 8.8 ± 2.4 | 8.8 ± 2.4 | 16.7 ± 1.9 | 16.7 ± 1.9 | 29.3 ± 4.2 | 29.3 ± 4.2 | 49.4 ± 6.3 | 49.4 ± 6.3 | 69.7 ± 7.2 | 69.7 ± 7.2 | 85.8 ± 3.3 | 85.8 ± 3.3 | <0.0001 |
| Blood count | |||||||||||||
| Red blood cells (106/ | 4.3 ± 0.1 | 4.1 ± 0.2 | 4.5 ± 0.1 | 4.2 ± 0.2 | 4.4 ± 0.2 | 4.3 ± 0.2 | 4.2 ± 0.1 | 4 ± 0.1 | 4 ± 0.3 | 4.1 ± 0.2 | 4 ± 0.2 | 4 ± 0.3 | NS |
| Hemoglobin (g/dL) | 14.4 ± 0.3 | 14 ± 0.2 | 14.5 ± 0.2 | 14.3 ± 0.1 | 15.1 ± 0.2 | 14.8 ± 0.1 | 15 ± 0.1 | 14.7 ± 0.3 | 14.2 ± 0.2 | 14.3 ± 0.1 | 14.1 ± 0.1 | 13.9 ± 0.1 | NS |
| White blood cells (103/ | 6.5 ± 0.4 | 6.3 ± 0.5 | 7.6 ± 0.3 | 6.9 ± 0.2 | 6.5 ± 0.6 | 6.9 ± 1.2 | 5.8 ± 0.4 | 5.9 ± 0.8 | 7.1 ± 0.6 | 6.8 ± 0.7 | 5.8 ± 0.4 | 6.2 ± 0.8 | NS |
| Platelets (103/ | 340 ± 21 | 352 ± 13 | 333 ± 18 | 308 ± 9 | 359 ± 14 | 342 ± 16 | 364 ± 17 | 355 ± 20 | 303 ± 13 | 294 ± 22 | 286 ± 14 | 254 ± 18 | NS |
| Blood biochemistry | |||||||||||||
| Na+ (mmol/L) | ND | ND | ND | ND | 142 ± 1.3 | 141 ± 0.9 | 140 ± 1.5 | 139 ± 1.1 | 141 ± 1.3 | 140 ± 1.5 | 140 ± 1 | 130 ± 1.4 | NS |
| K+ (mmol/L) | ND | ND | ND | ND | 4.4 ± 0.2 | 4.5 ± 0.1 | 4.3 ± 0.1 | 4.5 ± 0.1 | 4.5 ± 0.2 | 4.3 ± 0.1 | 4 ± 0.1 | 4.1 ± 0.1 | NS |
| Alanine transferase (U/L) | ND | ND | ND | ND | 23 ± 8 | 21 ± 6 | 26 ± 5 | 24 ± 9 | 29 ± 6 | 30 ± 5 | 31 ± 6 | 31 ± 8 | NS |
| Creatinine (mg/dL) | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.2 | NS |
| Chronic diseases | |||||||||||||
| Hypertension, n (%) | 0 | 0 | 0 | 0 | 2 (13) | (2) 13 | 4 (27) | 3 (20) | 4 (27) | 5 (33) | (4) 27 | (4) 27 | <0.0001 |
| Type 2 diabetes, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (7) | 0 | 5 (33) | 5 (33) | 3 (20) | 5 (33) | <0.0001 |
| Chronic heart disease, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 1 (7) | (4) 27 | (4) 27 | (4) 27 | 3 (20) | <0.0001 |
| Atherosclerosis, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (7) | 1 (7) | 2 (13) | 2 (13) | <0.0001 |
| Osteoporosis, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (7) | 1 (7) | 2 (13) | 2 (13) | 3 (20) | 2 (13) | <0.0001 |
Note: Results were analyzed using one-way ANOVA analysis of variance.
Abbreviations: ND, no data; NS, no significance.
Dental Examination of Healthy Subjects Aged 6–13, 14–19, 20–39, 40–59, 60–79, and 80–100
| 6–13 | 14–19 | 20–39 | 40–59 | 60–79 | 80–100 | ANOVA p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | ||
| (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | (n = 15) | ||
| Salivary flow (mL/min) | 0.45 ± 0.06 | 0.43 ± 0.08 | 0.45 ± 0.07 | 0.43 ± 0.05 | 0.42 ± 0.06 | 0.41 ± 0.06 | 0.45 ± 0.07 | 0.42 ± 0.08 | 0.27 ± 0.09 | 0.29 ± 0.1 | 0.25 ± 0.08 | 0,27 ± 0.12 | <0.0001 |
| DMFT | 3 ± 0.1 | 3 ± 0.4 | 15 ± 4 | 13 ± 6 | 18 ± 4 | 17 ± 4 | 18 ± 2 | 17 ± 4 | 30 ± 0.3 | 30 ± 0.2 | 30 ± 0.1 | 30 ± 0.2 | <0.0001 |
| dmft | 12 ± 0.3 | 10 ± 0.2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NS |
| PBI | 0 ± 0.1 | 0 ± 0.1 | 0 ± 0.1 | 0 ± 0.1 | 0.5 ± 0.3 | 0.4 ± 0.3 | 0.6 ± 0.3 | 0.6 ± 0.3 | 1.3 ± 0.4 | 1 ± 0.5 | 1.8 ± 0.3 | 1.4 ± 0.3 | <0.0001 |
| GI | 0 ± 0.1 | 0 ± 0.1 | 0 ± 0.3 | 0 ± 0.2 | 0.1 ± 0.3 | 0.1 ± 0.1 | 0.1 ± 0.2 | 0.1 ± 0.2 | 0.2 ± 0.1 | 0.2 ± 0.3 | 0.2 ± 0.2 | 0.2 ± 0.2 | <0.0001 |
Note: Results were analyzed using one-way ANOVA analysis of variance.
Abbreviations: dmft, decayed, missing, filled teeth for primary teeth; DMFT, decayed, missing, filled teeth for permanent teeth; GI, Gingival Index; n, number of patients; NA, not applicable; NS, no significance; PBI, Papilla Bleeding Index.
Figure 1Concentration of total thiols in saliva (A) and plasma (B), and protein carbonyls in saliva (C) and plasma (D) of males and females aged 6–13 (blue bars), 14–19 (red bars), 20–39 (green bar), 40–59 (purple bars), 60–79 (Orange bars), and 80–100 (black bars).
Figure 2Concentration of MGO in saliva (A) and plasma (B), CML in saliva (C) and plasma (D), and AGE in saliva (E) and plasma (F) of males and females aged 6–13 (blue bars), 14–19 (red bars), 20–39 (green bar), 40–59 (purple bars), 60–79 (Orange bars), and 80–100 (black bars).
Figure 3Concentration of CBL in saliva (A) and plasma (B) of males and females aged 6–13 (blue bars), 14–19 (red bars), 20–39 (green bar), 40–59 (purple bars), 60–79 (Orange bars), and 80–100 (black bars).
Figure 4Concentration of 4-HNE in saliva (A) and plasma (B), and 8-OHdG in saliva (C) and plasma (D) of male and female aged 6–13 (blue bars), 14–19 (red bars), 20–39 (green bar), 40–59 (purple bars), 60–79 (Orange bars), and 80–100 (black bars).
Figure 5Heat map of correlations between age, salivary, and plasma concentration of oxidation, glycation, and carbamylation of proteins, lipids, and DNA.
Multiple Regression Analysis of Oxidation, Glycation, and Carbamylation of Salivary and Plasma Proteins, Lipids, and DNA
| β1: Age | β2: Sex | ||||||
|---|---|---|---|---|---|---|---|
| Estimate | 95% CI | p-value | Estimate | 95% CI | p-value | ||
| Saliva | Total thiols level | −0.4503 | −0.5855 - −0.3151 | < 0.0001 | −1.344 | −8.958–6.27 | 0.728 |
| Protein carbonyls level | 0.02077 | 0.01454–0.027 | < 0.0001 | 0.06285 | −0.2879–0.4136 | 0.7241 | |
| MGO level | 0.008252 | 0.002732–0.01377 | 0.0036 | 0.03345 | −0.2773–0.3442 | 0.8321 | |
| CML level | 0.6253 | 0.4453–0.8053 | < 0.0001 | 12.34 | 2.204–22.47 | 0.0173 | |
| AGE level | 0.01658 | 0.01334–0.01982 | < 0.0001 | 0.2036 | 0.02129–0.3859 | 0.0288 | |
| CBL level | 0.01539 | 0.01067–0.02012 | < 0.0001 | −0.1421 | −0.4083–0.124 | 0.2934 | |
| 4-HNE level | 0.01584 | 0.01141–0.02026 | < 0.0001 | −0.05109 | −0.3003–0.1981 | 0.6863 | |
| 8-OHdG level | 0.02196 | 0.01783–0.02608 | < 0.0001 | −0.154 | −0.3862–0.07826 | 0.1924 | |
| Plasma | Total thiols level | −0.1152 | −0.1491 - −0.08128 | < 0.0001 | −0.2048 | −2.115–1.706 | 0.8327 |
| Protein carbonyls level | 0.09016 | 0.0628–0.1175 | < 0.0001 | −0.08927 | −1.63–1.452 | 0.9091 | |
| MGO level | 0.09579 | 0.0738–0.1178 | < 0.0001 | 0.5817 | −0.6561–1.82 | 0.355 | |
| CML level | 0.9321 | 0.6263–1.238 | < 0.0001 | 3.591 | −13.63–20.81 | 0.6812 | |
| AGE level | 0.01235 | 0.009662–0.01505 | < 0.0001 | −0.055 | −0.2066–0.0966 | 0.475 | |
| CBL level | 0.06489 | 0.04654–0.08325 | < 0.0001 | −1.139 | −2.173 - −0.106 | 0.0309 | |
| 4-HNE level | 0.03569 | 0.02855–0.04283 | < 0.0001 | −0.01329 | −0.4153–0.3887 | 0.948 | |
| 8-OHdG level | 0.02633 | 0.02141–0.03125 | < 0.0001 | −0.02482 | −0.302–0.2523 | 0.8599 | |
Abbreviations: AGE, advanced glycation end products; CBL, carbamyl-lysine; CI, confidence interval; CML, Nε-(carboxymethyl) lysine; MGO, methylglyoxal adducts; 4-HNE, 4-hydroxynonenal protein adducts; 8-OHdG, 8-hydroxy-2’-deoxyguanosine.
ROC Analysis of Oxidation, Glycation, and Carbamylation of Salivary and Plasma Proteins, Lipids, and DNA Between Children and Adolescents (Under 15 Years Old), the Working-Age Population (15–64 Years), and the Older People (65 Years and Older)
| Saliva | Total thiols level | 81.41 ± 30.21 | 81.04 ± 28.71 | > 76.88 | 0.5059 | 0.3948–0.6171 | 52.13 | 42.15% - 61.94% | 47.22 | 31.99% - 62.99% |
| Protein carbonyls level | 5.062 ± 0.9361 | 5.396 ± 1.026 | > 5.196 | 0.5975 | 0.4912–0.7038 | 59.57 | 49.47% - 68.93% | 55.56 | 39.58% - 70.46% | |
| MGO level | 2.999 ± 0.7768 | 2.992 ± 1.068 | > 2.985 | 0.5095 | 0.4066–0.6123 | 48.94 | 39.07% - 58.88% | 50 | 34.47% - 65.53% | |
| CML level | 84.36 ± 17.91 | 93.4 ± 29.93 | > 87.32 | 0.5969 | 0.4992–0.6947 | 57.45 | 47.35% - 66.96% | 55.56 | 39.58% - 70.46% | |
| AGE level | 1.902 ± 0.4671 | 2.334 ± 0.5523 | > 2.106 | 0.7284 | 0.6326–0.8242 | 65.96 | 55.92% - 74.74% | 69.44 | 53.14% - 82% | |
| CBL level | 3.174 ± 0.9666 | 3.298 ± 0.9684 | > 3.274 | 0.5322 | 0.4208–0.6436 | 51.06 | 41.12% - 60.93% | 50 | 34.47% - 65.53% | |
| 4-HNE level | 2.141 ± 0.9928 | 2.158 ± 0.7515 | > 2.164 | 0.5071 | 0.39–0.6241 | 52.13 | 42.15% - 61.94% | 50 | 34.47% - 65.53% | |
| 8-OHdG level | 1.975 ± 0.5078 | 2.333 ± 0.8316 | > 2.137 | 0.6188 | 0.5234–0.7142 | 55.32 | 45.26% - 64.96% | 58.33 | 42.2% - 72.86% | |
| Plasma | Total thiols level | 31.54 ± 6.349 | 28.26 ± 6.9 | < 29.25 | 0.6356 | 0.5333–0.738 | 57.45 | 47.35% - 66.96% | 61.11 | 44.86% - 75.22% |
| Protein carbonyls level | 10.41 ± 3.491 | 12.38 ± 5.1 | > 11.61 | 0.6117 | 0.5101–0.7133 | 56.38 | 46.3% - 65.96% | 58.33 | 42.2% - 72.86% | |
| MGO level | 9.496 ± 2.008 | 11.91 ± 4.407 | > 10.12 | 0.6723 | 0.5805–0.7641 | 62.77 | 52.67% - 71.86% | 61.11 | 44.86% - 75.22% | |
| CML level | 113.8 ± 42.49 | 142.7 ± 55.59 | > 124.7 | 0.6365 | 0.5377–0.7354 | 54.26 | 44.22% - 63.96% | 58.33 | 42.2% - 72.86% | |
| AGE level | 0.9947 ± 0.2352 | 1.177 ± 0.4672 | > 1.04 | 0.6203 | 0.5235–0.717 | 58.51 | 48.41% - 67.94% | 61.11 | 44.86% - 75.22% | |
| CBL level | 9.238 ± 2.304 | 10.32 ± 3.378 | > 9.486 | 0.594 | 0.4907–0.6972 | 56.38 | 46.3% - 65.96% | 61.11 | 44.86% - 75.22% | |
| 4-HNE level | 4.896 ± 1.271 | 5.621 ± 1.449 | > 5.176 | 0.6448 | 0.5435–0.7461 | 62.77 | 52.67% - 71.86% | 66.67 | 50.33% - 79.79% | |
| 8-OHdG level | 4.303 ± 0.9882 | 4.857 ± 1.06 | > 4.44 | 0.6516 | 0.5452–0.758 | 69.15 | 59.21% - 77.58% | 66.67 | 50.33% - 79.79% | |
| Saliva | Total thiols level | 81.41 ± 30.21 | 54.38 ± 16.36 | < 65.45 | 0.8011 | 0.6996–0.9027 | 78 | 64.76% - 87.25% | 77.78 | 61.92% - 88.28% |
| Protein carbonyls level | 5.062 ± 0.9361 | 6.58 ± 1.585 | > 5.75 | 0.7889 | 0.6956–0.8821 | 68 | 54.19% - 79.24% | 72.22 | 56.01% - 84.15% | |
| MGO level | 2.999 ± 0.7768 | 3.628 ± 1.157 | > 3.251 | 0.69 | 0.5778–0.8022 | 64 | 50.14% - 75.86% | 66.67 | 50.33% - 79.79% | |
| CML level | 84.36 ± 17.91 | 127.6 ± 50.99 | > 95.49 | 0.7828 | 0.6811–0.8844 | 74 | 60.45% - 84.13% | 77.78 | 61.92% - 88.28% | |
| AGE level | 1.902 ± 0.4671 | 3.164 ± 0.8527 | > 2.361 | 0.9056 | 0.8418–0.9693 | 84 | 71.49% - 91.66% | 86.11 | 71.34% - 93.92% | |
| CBL level | 3.174 ± 0.9666 | 4.156 ± 0.7893 | > 3.698 | 0.7794 | 0.6779–0.881 | 68 | 54.19% - 79.24% | 72.22 | 56.01% - 84.15% | |
| 4-HNE level | 2.141 ± 0.9928 | 3.245 ± 0.8189 | > 2.562 | 0.8117 | 0.7162–0.9071 | 80 | 66.96% - 88.76% | 75 | 58.93% - 86.25% | |
| 8-OHdG level | 1.975 ± 0.5078 | 3.616 ± 0.8396 | > 2.55 | 0.9622 | 0.9218–1 | 92 | 81.16% - 96.85% | 91.67 | 78.17% - 97.13% | |
| Plasma | Total thiols level | 31.54 ± 6.349 | 23.45 ± 6.486 | < 26.97 | 0.82 | 0.7303–0.9097 | 74 | 60.45% - 84.13% | 77.78 | 61.92% - 88.28% |
| Protein carbonyls level | 10.41 ± 3.491 | 16.8 ± 6.672 | > 12.64 | 0.7878 | 0.6919–0.8837 | 72 | 58.33% - 82.53% | 75 | 58.93% - 86.25% | |
| MGO level | 9.496 ± 2.008 | 16.18 ± 5.491 | > 11.67 | 0.8817 | 0.8062–0.9571 | 80 | 66.96% - 88.76% | 83.33 | 68.11% - 92.13% | |
| CML level | 113.8 ± 42.49 | 187.2 ± 72.72 | > 145.1 | 0.8067 | 0.7149–0.8984 | 78 | 64.76% - 87.25% | 77.78 | 61.92% - 88.28% | |
| AGE level | 0.9947 ± 0.2352 | 1.834 ± 0.7526 | > 1.136 | 0.8778 | 0.8057–0.9499 | 82 | 69.2% - 90.23% | 80.56 | 64.97% - 90.25% | |
| CBL level | 9.238 ± 2.304 | 13.81 ± 4.623 | > 10.36 | 0.7883 | 0.6925–0.8842 | 72 | 58.33% - 82.53% | 75 | 58.93% - 86.25% | |
| 4-HNE level | 4.896 ± 1.271 | 7.403 ± 1.462 | > 5.935 | 0.9006 | 0.8344–0.9667 | 88 | 76.2% - 94.38% | 86.11 | 71.34% - 93.92% | |
| 8-OHdG level | 4.303 ± 0.9882 | 6.125 ± 0.8617 | > 5.25 | 0.9128 | 0.8531–0.9724 | 82 | 69.2% - 90.23% | 80.56 | 64.97% - 90.25% | |
| Saliva | Total thiols level | 81.04 ± 28.71 | 54.38 ± 16.36 | < 61.31 | 0.8085 | 0.737–0.8801 | 74 | 60.45% - 84.13% | 78.72 | 69.41% - 85.78% |
| Protein carbonyls level | 5.396 ± 1.026 | 6.58 ± 1.585 | > 5.832 | 0.7274 | 0.6368–0.8181 | 68 | 54.19% - 79.24% | 63.83 | 53.75% - 72.82% | |
| MGO level | 2.992 ± 1.068 | 3.628 ± 1.157 | > 3.387 | 0.6532 | 0.5601–0.7463 | 62 | 48.15% - 74.14% | 62.77 | 52.67% - 71.86% | |
| CML level | 93.4 ± 29.93 | 127.6 ± 50.99 | > 102 | 0.7166 | 0.6182–0.815 | 66 | 52.15% - 77.56% | 62.77 | 52.67% - 71.86% | |
| AGE level | 2.334 ± 0.5523 | 3.164 ± 0.8527 | > 2.62 | 0.7981 | 0.7151–0.881 | 76 | 62.59% - 85.7% | 73.4 | 63.68% - 81.29% | |
| CBL level | 3.298 ± 0.9684 | 4.156 ± 0.7893 | > 3.793 | 0.7455 | 0.6656–0.8254 | 64 | 50.14% - 75.86% | 68.09 | 58.11% - 76.64% | |
| 4-HNE level | 2.158 ± 0.7515 | 3.245 ± 0.8189 | > 2.71 | 0.8413 | 0.7759–0.9066 | 74 | 60.45% - 84.13% | 78.72 | 69.41% - 85.78% | |
| 8-OHdG level | 2.333 ± 0.8316 | 3.616 ± 0.8396 | > 2.986 | 0.8566 | 0.7943–0.9189 | 76 | 62.59% - 85.7% | 80.85 | 71.75% - 87.53% | |
| Plasma | Total thiols level | 28.26 ± 6.9 | 23.45 ± 6.486 | < 25.04 | 0.7011 | 0.611–0.7911 | 68 | 54.19% - 79.24% | 72.34 | 62.56% - 80.37% |
| Protein carbonyls level | 12.38 ± 5.1 | 16.8 ± 6.672 | > 14.06 | 0.7051 | 0.6102–0.8 | 68 | 54.19% - 79.24% | 68.09 | 58.11% - 76.64% | |
| MGO level | 11.91 ± 4.407 | 16.18 ± 5.491 | > 13.58 | 0.7474 | 0.6598–0.8351 | 72 | 58.33% - 82.53% | 72.34 | 62.56% - 80.37% | |
| CML level | 142.7 ± 55.59 | 187.2 ± 72.72 | > 163.3 | 0.6832 | 0.5892–0.7772 | 62 | 48.15% - 74.14% | 64.89 | 54.83% - 73.78% | |
| AGE level | 1.177 ± 0.4672 | 1.834 ± 0.7526 | > 1.429 | 0.7823 | 0.7011–0.8636 | 72 | 58.33% - 82.53% | 75.53 | 65.95% - 83.11% | |
| CBL level | 10.32 ± 3.378 | 13.81 ± 4.623 | > 11.36 | 0.7177 | 0.6229–0.8124 | 68 | 54.19% - 79.24% | 69.15 | 59.21% - 77.58% | |
| 4-HNE level | 5.621 ± 1.449 | 7.403 ± 1.462 | > 6.52 | 0.8123 | 0.7367–0.8879 | 80 | 66.96% - 88.76% | 75.53 | 65.95% - 83.11% | |
| 8-OHdG level | 4.857 ± 1.06 | 6.125 ± 0.8617 | > 5.476 | 0.8247 | 0.7583–0.891 | 76 | 62.59% - 85.7% | 74.47 | 64.81% - 82.2% | |
Note: *Expressed as mean ± standard deviation (SD).
Abbreviations: AGE, advanced glycation end products; AUC, the area under the curve; CBL, carbamyl-lysine; CI, confidence interval; CML, Nε-(carboxymethyl) lysine; MGO, methylglyoxal adducts; SD, standard deviation; 4-HNE, 4-hydroxynonenal protein adducts; 8-OHdG, 8-hydroxy-2’-deoxyguanosine; 15–64, the working-age population (15–64 years); < 15, children and young adolescents (under 15 years old); > 64, the elderly population (65 years and older).